Ipsen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Ipsen wird ein jährliches Gewinn- und Umsatzwachstum von 7% bzw. 5.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 6.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 14.8% betragen.

Wichtige Informationen

7.0%

Wachstumsrate der Gewinne

6.9%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	23.9%
Wachstumsrate der Einnahmen	5.5%
Zukünftige Eigenkapitalrendite	14.8%
Analystenabdeckung	Good
Zuletzt aktualisiert	04 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

OTCPK:IPSE.Y - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	3,932	802	848	1,109	11
12/31/2025	3,686	730	794	1,020	12
12/31/2024	3,490	627	630	849	13
6/30/2024	3,435	664	425	903	N/A
3/31/2024	3,371	641	554	884	N/A
12/31/2023	3,306	617	683	866	N/A
6/30/2023	3,282	406	764	972	N/A
3/31/2023	3,219	500	741	971	N/A
12/31/2022	3,156	593	719	971	N/A
9/30/2022	3,053	656	615	972	N/A
6/30/2022	2,950	719	512	973	N/A
3/31/2022	2,849	675	494	933	N/A
12/31/2021	2,749	631	475	893	N/A
9/30/2021	2,712	626	570	860	N/A
6/30/2021	2,676	622	665	827	N/A
3/31/2021	2,681	585	649	799	N/A
12/31/2020	2,686	548	632	771	N/A
9/30/2020	2,697	249	564	750	N/A
6/30/2020	2,707	-50	496	729	N/A
3/31/2020	2,700	-53	421	678	N/A
12/31/2019	2,693	-55	347	628	N/A
9/30/2019	2,605	176	310	591	N/A
6/30/2019	2,516	406	272	555	N/A
3/31/2019	2,432	397	279	563	N/A
12/31/2018	2,348	388	285	571	N/A
9/30/2018	2,258	365	N/A	N/A	N/A
6/30/2018	2,167	343	280	502	N/A
3/31/2018	2,090	307	N/A	463	N/A
12/31/2017	2,012	270	N/A	423	N/A
9/30/2017	1,923	243	N/A	N/A	N/A
6/30/2017	1,834	217	N/A	316	N/A
3/31/2017	1,753	221	N/A	317	N/A
12/31/2016	1,671	226	N/A	318	N/A
9/30/2016	1,623	229	N/A	N/A	N/A
6/30/2016	1,575	233	N/A	318	N/A
3/31/2016	1,548	211	N/A	271	N/A
12/31/2015	1,520	189	N/A	224	N/A
9/30/2015	1,468	165	N/A	225	N/A
6/30/2015	1,416	140	N/A	227	N/A
3/31/2015	1,374	147	N/A	237	N/A
12/31/2014	1,332	154	N/A	246	N/A
9/30/2014	1,310	155	N/A	217	N/A
6/30/2014	1,287	156	N/A	188	N/A
3/31/2014	1,284	149	N/A	188	N/A
12/31/2013	1,282	142	N/A	188	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IPSE.YDas prognostizierte Gewinnwachstum (7% pro Jahr) liegt über der Sparquote (2.6%).

Ertrag vs. Markt: IPSE.YDie Erträge des Unternehmens (7% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (15.2% pro Jahr).

Hohe Wachstumserträge: IPSE.YDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: IPSE.YDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: IPSE.YDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: IPSE.YDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (14.8%).

Ipsen Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen S.A. Provides Sales Guidance for the Year 2022

Recent updates

Ipsen S.A. to Report Fiscal Year 2024 Results on Feb 13, 2025

Ipsen Provides Update on CONTACT-02 Phase III Trial in Metastatic Castration-Resistant Prostate Cancer Following Final Overall Survival Analysis

Ipsen Receives CHMPPositive Opinions for Iqirvo® (Elafibranor) in Primary Biliary Cholangitis and Kayfanda® (Odevixibat) in Alagille Syndrome, Two Rare Cholestatic Liver Diseases

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2024

Genfit S.A. Announces the Successful Corporate Milestone with U.S. FDA Accelerated Approval of Ipsen's Iqirvo for Primary Biliary Cholangitis

Ipsen S.A. Approves Dividend, Payable on 3 June 2024

Ipsen Announces Executive Changes

Ipsen’s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA

Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024

Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC

Ipsen and GENFIT Announces Full Results from the Pivotal Phase III ELATIVE Trial

Ipsen S.A. to Report Q4, 2023 Results on Feb 08, 2024

Ipsen S.A. to Report First Half, 2024 Results on Jul 24, 2024

IRLAB Therapeutics AB Announces Further Information on Results from Mesdopetam’s Clinical Phase IIb Study in Parkinson’s Disease Levodopa-Induced Dyskinesias and Phase III Preparatory Phase I Studies Performed by Ipsen

Ipsen Provides Update on E.U. Marketing Authorization Application for Bylvay for Cholestatic Pruritus in Patients with Alagille Syndrome

Ipsen Announces European Commission Decision on Palovarotene for the Treatment of FOP

Ipsen and GENFIT Announces Positive Results from Phase III ELATIVE Trial of Elafibranor in Patients with Primary Biliary Cholangitis, A Rare Cholestatic Liver Disease

Ipsen Announces U.S. FDA Submission Acceptance of Its Supplemental New Drug Application for Onivyde Regimen in First-Line Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen Announces U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen to Present New Data

Ipsen S.A. Approves Dividend, Payable on 6 June 2023

Ipsen S.A. Proposes Final Dividend for the Financial Year 2022, Payable on June 6, 2023

Ipsen S.A. Provides Earnings Guidance for the Full Year 2023

Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U

Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde(R) Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma At Asco GI

Ipsen S.A. (ENXTPA:IPN) entered into a definitive merger agreement to acquire Albireo Pharma, Inc. (NasdaqCM:ALBO) for approximately $870 million.

Ipsen S.A. Provides Update on Phase III CONTACT-01 Trial Evaluating Cabozantinib

Ipsen Announces Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Ipsen S.A. Provides Earnings Guidance for the Financial Year 2023

Ipsen S.A. to Report Fiscal Year 2022 Results on Feb 09, 2023

Ipsen S.A. to Report Q2, 2023 Results on Jul 27, 2023

Ipsen S.A. to Report Q3, 2022 Results on Oct 26, 2022

Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde in Second-Line Monotherapy for Small Cell Lung Cancer

Ipsen S.A. Upgrades Earnings Guidance for the Full Year 2022

Ipsen Announces U.S. FDA Priority Review for Palovarotene New Drug Application in Patients with Fibrodysplasia Ossificans Progressiva Following Resubmission

Ipsen Announces at ASCO 2022 New Cabometyx Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Approves Dividend, Payable on 2 June 2022

Ipsen S.A. Proposes Dividend for the Financial Year 2021, payable on 2 June 2022

Exelixis, Inc. Partner Ipsen Receives European Commission Approval for Cabometyx® (Cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer

Ipsen S.A. Provides Sales Guidance for the Year 2022

Ipsen Appoints Catherine Abi-Habib as EVP Strategy, Transformation, and Digital

Ipsen S.A. Announces Two-Year Follow-Up Results from Analyses of the Phase III Checkmate -9ER Trial

Ipsen S.A. Proposes Dividend for the Year 2021

Ipsen Announces the Health Canada Approval of Sohonos as the First Treatment for Fibrodysplasia Ossificans Progressiva

Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer

Ipsen Announces Withdrawal of Palovarotene NDA, Confirming Intention to Re-Submit Following Additional Data Analyses

Exelixis and Ipsen Announce Detailed Results from Phase 3 COSMIC-311 Pivotal Trial of Cabozantinib in Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer Presented at ASCO 2021

Ipsen S.A. Confirms U.S. Fda Accepts New Drug Application for Palovarotene as the First Potential Treatment Worldwide for Fibrodysplasia Ossificans Progressiva (Fop)

Ipsen Opts-In to Join Exelixis, Inc With Ongoing Development of Cabometyx® for People Living With a Form of Thyroid Cancer, Based on Promising Interim Results

Ipsen Receives Positive CHMP Opinion Recommending Cabometyx® in Combination with Opdivo® as First-Line Treatment for Patients Living with Advanced Renal Cell Carcinoma

Ipsen Announces New Data from the Phase II CLARINET FORTE Study Which Demonstrated Preservation of Quality of Life When Increasing Dose Frequencies of Somatuline Autogel (lanreotide)

Ipsen S.A. Announces New Data From Pivotal Phase III CheckMate -9ER trial of Cabometyx®

Ipsen to Showcase Commitment to Going Beyond Traditional Outcome Measures for Patients Living with Renal Cell Carcinoma At ASCO GU 2021

Ipsen Appoints Gwenan White as Executive Vice President Communications and Public Affairs

Ipsen Announces New Analyses of Pivotal Phase III Trial Data Highlight Long Duration of Response for Dysport (Abobotulinumtoxina) in Five Therapeutic Indications

Ipsen S.A. to Report Fiscal Year 2020 Results on Feb 11, 2021

Ipsen to Present 12 Abstracts at the 11th World Congress for Neurorehabilitation (WCNR) Virtual Congress Taking Place Jointly With the 35th Congress of the French Society of Physical and Rehabilitation Medicine (SOFMER)1-13

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer

Ipsen Announces First Presentation of Results from the Pivotal Phase III CheckMate -9ER Trial

Ipsen Announces the Release of First Efficacy and Safety Data from the Clarinet Forte Study

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken